Ultrasensitive bioassaying of HER-2 protein for diagnosis of breast cancer using reduced graphene oxide/chitosan as nanobiocompatible platform

Nasrollahpour, Hassan; IŞILDAK, İbrahim; Rashidi, Mohammad-Reza; Hashemi, Esmat; Naseri, Abdolhosein; Khalilzadeh, Balal

doi:10.1186/s12645-021-00082-y

Ultrasensitive bioassaying of HER-2 protein for diagnosis of breast cancer using reduced graphene oxide/chitosan as nanobiocompatible platform

Nasrollahpour H., IŞILDAK İ. , Rashidi M., Hashemi E. A. , Naseri A., Khalilzadeh B.

CANCER NANOTECHNOLOGY, vol.12, no.1, 2021 (Journal Indexed in SCI)

Publication Type: Article / Article
Volume: 12 Issue: 1
Publication Date: 2021
Doi Number: 10.1186/s12645-021-00082-y
Title of Journal : CANCER NANOTECHNOLOGY
Keywords: HER-2, ECL, Bioassay, Breast cancer, Biomedical analysis, Ruthenium, Protein, Biocompatible polymer, Chitosan, Biotechnology, [Ru(bpy)(3)](2+)

Abstract

Background: In this label-free bioassay, an electrochemiluminescence (ECL) immunosensor was developed for the quantification of breast cancer using HER-2 protein as a metastatic biomarker.